Ultrasonographic fatty liver indicator (US-FLI): a reliable biomarker for non-invasive NAFLD stratification

Abstract

Here, we comment on a recent article supporting the use of the ultrasonographic fatty liver indicator (US-FLI) as a point-of-care biomarker to be used in the community to rule out nonalcoholic steatohepatitis (NASH). To this end, we discuss definitions and characteristics of US-FLI, and we critically summarize the principal studies published from 2012 to 2023. We conclude that US-FLI exhibits high reproducibility. It finds utility across both the pediatric population and the point-of-care settings. Furthermore, it demonstrates a robust correlation with metabolic derangements, and also serves as a predictive tool for varying grades of hepatic steatosis and important liver histology endpoints. Notably, it excels in its capacity to differentiate between bland steatosis and true NASH. However, US-FLI reportedly exhibits limited accuracy among patient populations with obesity. Finally, we propose a detailed agenda to advance research on US-FLI.

Keywords

Liver biopsy / NAFLD / NASH / ultrasonography

References

[1] Italian Association for the Study of the Liver (AISF)AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions.Dig Liver Dis2017;49:471-83

[2] Wang D,Zhu Z.Changes in the global, regional, and national burdens of NAFLD from 1990 to 2019: a systematic analysis of the global burden of disease study 2019.Front Nutr2022;9:1047129 PMCID:PMC9811393

[3] Singh S,Wang Z,Murad MH.Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.Clin Gastroenterol Hepatol2015;13:643-54.e1 PMCID:PMC4208976

[4] Lonardo A.Perspectives of nonalcoholic fatty liver disease research: a personal point of view. Explor Med. 2020:1:85-107. 10.37349/emed.2020.00007.

[5] Yoshizawa E.MRI-derived proton density fat fraction.J Med Ultrason (2001)2021;48:497-506

[6] Ladd ME,Meyerspeer M.Pros and cons of ultra-high-field MRI/MRS for human application.Prog Nucl Magn Reson Spectrosc2018;109:1-50

[7] Nelson SM,Lisanti C.Ultrasound fatty liver indicator: a simple tool for differentiating steatosis from nonalcoholic steatohepatitis: validity in the average obese population.J Ultrasound Med2020;39:749-59

[8] Radonjić T,Zdravković M.Point-of-care abdominal ultrasonography (POCUS) on the way to the right and rapid diagnosis.Diagnostics2022;12:2052 PMCID:PMC9497677

[9] Ballestri S,Romagnoli D.Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD.Liver Int2012;32:1242-52

[10] Sourianarayanane A.Accuracy of ultrasonographic fatty liver index using point-of-care ultrasound in stratifying non-alcoholic fatty liver disease patients.Eur J Gastroenterol Hepatol2023;35:654-61

[11] Ballestri S,Baldelli E.Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases.Metabolism2017;72:57-65

[12] Liu HK,Su YT.Novel ultrasonographic fatty liver indicator can predict hepatitis in children with non-alcoholic fatty liver disease.Front Pediatr2018;6:416 PMCID:PMC6331417

[13] Xavier SA,Arieira CM.US-FLI score - Is it possible to predict the steatosis grade with an ultrasonographic score?.Mol Genet Metab2021;132:204-9

[14] Lonardo A,Bedogni G,Tiribelli C.The fatty liver index (FLI) 15 years later: a reappraisal.Metab Target Organ Damage2021;1:10.

[15] Ballestri S,Baldelli E.Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease.Diagnostics2021;11:98 PMCID:PMC7827076

[16] Ballestri S,Girolamo MD,Capitelli M.Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality.Metab Target Organ Damage2023;3:1.

[17] Yi M,Feng X.Extrahepatic morbidities and mortality of NAFLD: an umbrella review of meta-analyses.Aliment Pharmacol Ther2022;56:1119-30

[18] Konyn P,Dennis BB,Ahmed A.Gallstone disease and its association with nonalcoholic fatty liver disease, all-cause and cause-specific mortality.Clin Gastroenterol Hepatol2023;21:940-948.e2

[19] Kim YK,Her KH.The grade of nonalcoholic fatty liver disease is an independent risk factor for gallstone disease: an observational study.Medicine2019;98:e16018 PMCID:PMC6635222

[20] Yilmaz Y,Akin H.Gallstone disease does not predict liver histology in nonalcoholic fatty liver disease.Gut Liver2014;8:313-7 PMCID:PMC4026650

[21] Colak Y,Erim T.Impaired gallbladder motility and increased gallbladder wall thickness in patients with nonalcoholic fatty liver disease.J Neurogastroenterol Motil2016;22:470-6 PMCID:PMC4930302

[22] Tarantino G,Di Vito C.Association of NAFLD and Insulin resistance with non metastatic bladder cancer patients: a cross-sectional Retrospective study.J Clin Med2021;10:346 PMCID:PMC7831331

[23] Mantovani A,Beatrice G.Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies.Gut2022;71:778-88

[24] Mantovani A,Tilg H,Targher G.Comparative effects of non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease on risk of incident cardiovascular events: a meta-analysis of about 13 million individuals.Gut2023;72:1433-6

[25] Tarantino G,Balsano C.Liver-spleen axis in nonalcoholic fatty liver disease.Expert Rev Gastroenterol Hepatol2021;15:759-69

[26] Newsome PN,Deeks JJ.FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.Lancet Gastroenterol Hepatol2020;5:362-73 PMCID:PMC7066580